RET and thyroid gland carcinoma: A recent study by our group showed that the BRAF-inhibitor PLX4720 reduced CXCL8 secretion in several BRAFV600E mutated thyroid cancer cell lines (8505C, 8305C, BCPAP), but not in RET/PTC rearranged ones (TPC1) [110].